Xunfei Healthcare Sells 6% of Beijing Huiji for RMB1.53 Million; Retains Control with 49% Stake

Bulletin Express
06/18

Xunfei Healthcare Technology Co., Ltd. announced a connected transaction under which new investor Sanya Gaozhuo Jiayin Information Technology Partnership will inject RMB1.53 million into Beijing Huiji Intelligent Medical Technology Co., Ltd.

Key terms • Investment structure: RMB1.29 million will be booked as new registered capital, lifting Beijing Huiji’s capital base from RMB20.28 million to RMB21.57 million; the remaining RMB0.23 million will enter the capital reserve. • Equity change: Xunfei Healthcare’s holding in Beijing Huiji will fall from 52.13% to 49.00%, while Sanya Gaozhuo Jiayin will acquire a 6.00% interest; Tianjin Huizhi and Wu Ji will hold 35.60% and 9.40%, respectively. • Control and accounting: Xunfei Healthcare will maintain effective control; Beijing Huiji will remain fully consolidated. The deemed disposal will be treated as an equity transaction with no gain or loss recorded in the income statement.

Connected-party background Sanya Gaozhuo Jiayin is an associate of Mr. Xu Jingming, a 15.47% shareholder of Xunfei Healthcare and executive partner of the investing entity. The transaction therefore constitutes a connected transaction under Chapter 14A and a deemed disposal under Rule 14.29 of the Hong Kong Listing Rules. With the highest applicable percentage ratio below 5%, the deal requires public announcement but not independent shareholders’ approval.

Beijing Huiji financial snapshot • FY 2024 net loss: RMB18.12 million (before tax), RMB14.61 million (after tax) • FY 2025 net loss: RMB34.86 million (before tax), RMB30.00 million (after tax) • 31 Dec 2025 unaudited net assets: negative RMB27.18 million

Strategic rationale Management expects the capital injection to optimise Beijing Huiji’s capital structure, bolster working capital and introduce strategic resources to strengthen its market positioning. No director was required to abstain from the board vote, and the board views the terms as fair and reasonable and in the interests of all shareholders.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10